$72.94-1.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $340.5M | $207.6M | +63.97% |
| Profit | $126.8M | $19.7M | +544.59% |
| Profit per share | $1.01 | $0.16 | +531.25% |
| Free Cash Flow | $142.2M | $54.5M | +160.98% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders. We have discovered more than 1,000 proprietary selective glucocorticoid receptor antagonists. Our development activities include advanced clinical trials in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease. In 2012, we introduced Korlym, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing’s syndrome. In March 2026, we introduced Lifyorli ® as a treatment for patients with platinum-resistant ovarian cancer. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist. We are headquartered in Redwood City, California.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Corcept Therapeutics Inc.’s Item 2.02 8-K filed November 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Corcept Therapeutics Inc. reported on November 3, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From Corcept Therapeutics Inc.'s results release of November 3, 2026; its quarterly report has since been filed.
Actual
$340.5M
+64% y/y
+33% q/q
Guided
—
No guide given
Actual
$1.01
+181% q/q
Guided
—
No guide given
Actual
$114.7M
+178% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.